Penn Davis Mcfarland Inc. boosted its place in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1,176.7% through the third quarter, HoldingsChannel.com reviews. The institutional investor owned 19,150 shares of the medical analysis firm’s inventory after buying a further 17,650 shares through the quarter. Penn Davis Mcfarland Inc.’s holdings in Amgen had been value $6,170,000 as of its most up-to-date SEC submitting.
A lot of different institutional buyers and hedge funds have additionally not too long ago purchased and offered shares of the enterprise. AdvisorNet Monetary Inc boosted its stake in Amgen by 5.7% within the first quarter. AdvisorNet Monetary Inc now owns 2,206 shares of the medical analysis firm’s inventory valued at $627,000 after buying a further 119 shares through the interval. Austin Non-public Wealth LLC boosted its place in Amgen by 4.3% through the 1st quarter. Austin Non-public Wealth LLC now owns 1,023 shares of the medical analysis firm’s inventory valued at $281,000 after buying a further 42 shares through the interval. Annex Advisory Companies LLC grew its stake in Amgen by 1.9% through the 1st quarter. Annex Advisory Companies LLC now owns 15,091 shares of the medical analysis firm’s inventory value $4,291,000 after shopping for a further 285 shares over the last quarter. Riverview Belief Co elevated its place in Amgen by 11.0% within the first quarter. Riverview Belief Co now owns 1,006 shares of the medical analysis firm’s inventory value $286,000 after shopping for a further 100 shares through the interval. Lastly, Mechanics Financial institution Belief Division lifted its stake in Amgen by 4.4% within the first quarter. Mechanics Financial institution Belief Division now owns 5,433 shares of the medical analysis firm’s inventory valued at $1,545,000 after shopping for a further 229 shares over the last quarter. Hedge funds and different institutional buyers personal 76.50% of the corporate’s inventory.
Analyst Scores Modifications
A number of analysis corporations have not too long ago commented on AMGN. Sanford C. Bernstein assumed protection on shares of Amgen in a report on Thursday. They issued an “outperform” ranking and a $380.00 worth goal on the inventory. Oppenheimer restated an “outperform” ranking and issued a $380.00 worth goal on shares of Amgen in a analysis notice on Wednesday, August seventh. Jefferies Monetary Group reiterated a “purchase” ranking and set a $380.00 worth goal (up from $375.00) on shares of Amgen in a analysis report on Wednesday, August seventh. Barclays upped their worth goal on shares of Amgen from $300.00 to $315.00 and gave the inventory an “equal weight” ranking in a report on Monday, October seventh. Lastly, Argus raised their goal worth on shares of Amgen from $300.00 to $340.00 and gave the corporate a “purchase” ranking in a analysis notice on Thursday, June twenty seventh. One analysis analyst has rated the inventory with a promote ranking, eleven have assigned a maintain ranking, twelve have issued a purchase ranking and one has assigned a powerful purchase ranking to the inventory. Based on information from MarketBeat, the inventory presently has a mean ranking of “Average Purchase” and a consensus worth goal of $332.45.
Get Our Newest Report on Amgen
Amgen Inventory Efficiency
Shares of AMGN opened at $321.66 on Monday. The corporate has a market capitalization of $172.55 billion, a PE ratio of 45.95, a PEG ratio of two.86 and a beta of 0.61. The corporate has a debt-to-equity ratio of 9.64, a fast ratio of 0.89 and a present ratio of 1.26. The corporate’s 50 day shifting common worth is $326.07 and its 200 day shifting common worth is $312.41. Amgen Inc. has a 52 week low of $249.70 and a 52 week excessive of $346.85.
Amgen (NASDAQ:AMGN – Get Free Report) final posted its quarterly earnings outcomes on Tuesday, August sixth. The medical analysis firm reported $4.97 earnings per share for the quarter, lacking analysts’ consensus estimates of $5.01 by ($0.04). The corporate had income of $8.39 billion through the quarter, in comparison with analyst estimates of $8.35 billion. Amgen had a return on fairness of 161.72% and a web margin of 10.12%. The corporate’s income was up 20.1% in comparison with the identical quarter final 12 months. Throughout the identical interval final 12 months, the corporate posted $5.00 earnings per share. Analysis analysts count on that Amgen Inc. will put up 19.49 EPS for the present fiscal 12 months.
Amgen Dividend Announcement
The corporate additionally not too long ago declared a quarterly dividend, which was paid on Tuesday, August sixth. Stockholders of file on Friday, August sixteenth had been issued a dividend of $2.25 per share. The ex-dividend date was Friday, August sixteenth. This represents a $9.00 annualized dividend and a dividend yield of two.80%. Amgen’s dividend payout ratio is 128.57%.
Amgen Firm Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The corporate’s principal merchandise embody Enbrel to deal with plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the remedy of grownup sufferers with plaque psoriasis, psoriatic arthritis, and oral ulcers related to Behçet’s illness; Prolia to deal with postmenopausal ladies with osteoporosis; XGEVA for skeletal-related occasions prevention; Repatha, which reduces the dangers of myocardial infarction, stroke, and coronary revascularization; Nplate for the remedy of sufferers with immune thrombocytopenia; KYPROLIS to deal with sufferers with relapsed or refractory a number of myeloma; Aranesp to deal with a lower-than-normal variety of crimson blood cells and anemia; EVENITY for the remedy of osteoporosis in postmenopausal for women and men; Vectibix to deal with sufferers with wild-type RAS metastatic colorectal most cancers; BLINCYTO for the remedy of sufferers with acute lymphoblastic leukemia; TEPEZZA to deal with thyroid eye illness; and KRYSTEXXA for the remedy of persistent refractory gout.
Additional Studying
Wish to see what different hedge funds are holding AMGN? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Obtain Information & Scores for Amgen Day by day – Enter your electronic mail handle beneath to obtain a concise every day abstract of the most recent information and analysts’ rankings for Amgen and associated firms with MarketBeat.com’s FREE every day electronic mail e-newsletter.
